CymaBay Therapeutics Inc. (CBAY)
(Delayed Data from NSDQ)
$13.12 USD
+0.67 (5.38%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.12 USD
+0.67 (5.38%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
by Zacks Equity Research
Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include AINV, BLDP, CBAY, FATE and OCLR.
Progenics Pharmaceuticals (PGNX) in Focus: Stock Gains 8.3%
by Zacks Equity Research
Progenics Pharmaceuticals (PGNX) saw its shares rise above 8% in the last trading session.
The Zacks Analyst Blog Highlights: Cymabay Therapeutics, Attunity, Lumentum Holdings, Datawatch and Arconic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cymabay Therapeutics, Attunity, Lumentum Holdings, Datawatch and Arconic
5 Top Performers of Trump's First 30 Days in Office
by Swarup Gupta
Trump indicated these gains were largely attributable to the positive sentiment generated by his victory.
New Strong Buy Stocks for February 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Can The Uptrend Continue for Cymabay Therapeutics (CBAY)?
by Zacks Equity Research
Investors certainly have to be happy with Cymabay Therapeutics, Inc. (CBAY) and its short term performance
Cerner's EHR Platform to Enhance Health Care at San Juan NGO
by Zacks Equity Research
Cerner Corporation (CERN) announced that it recently entered into an agreement to provide San Juan Regional Medical Center with a new electronic health record platform.
5 Breakout Stocks for Superior Returns
by Swarup Gupta
If properly implemented, such a strategy could deliver impressive returns.
Cymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher
by Zacks Equity Research
Cymabay Therapeutics, Inc. (CBAY) shares rose over 9% in the last trading session.